Sebia

Sebia a global diagnostic company, develops, manufactures and commercializes IVD tests and analyzers dedicated cancer, diabetes and hemoglobin disorders. Sebia focuses on both agarose gel and capillary assays, and their dedicated automation, to integrate into the same routine workflow. More recently Sebia completed its Myeloma line, with two important additions, Hydrashift daratumumab, to be used with the Hydragel IF test to mitigate the DARZALEX® interference, and two new generations sFLC assays, Seralite serum and Sebia FLC kappa and lambda kits.